InspireMD Announces Completion Of Enrollment In C-Guardians U.S. Investigational Device Exemption Clinical Trial
Portfolio Pulse from Happy Mohamed
InspireMD has completed enrollment for its C-Guardians U.S. Investigational Device Exemption clinical trial, aimed at supporting potential U.S. marketing approval of the CGuard Prime EPS stent system. The company expects study results and Premarket Approval submission in H2 2024, with potential U.S. approval in H1 2025.
June 26, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InspireMD's completion of enrollment for the C-Guardians clinical trial brings the company closer to potential U.S. approval of the CGuard Prime EPS stent system, with results expected in H2 2024.
The completion of enrollment for the C-Guardians clinical trial is a significant milestone for InspireMD, as it brings the company closer to potential U.S. approval of the CGuard Prime EPS stent system. Positive results from the trial could lead to increased investor interest and a potential boost in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100